No to CF drug Orkambi at cost of €391 million over five years

Funding denied despite CF sufferers pleas for access

Susan Mitchell

Deputy Editor and Health Editor @susmitchellsbp
1st June, 2016
Deal or no deal? Orkambi

The state’s drug assessment watchdog has recommended against funding the cystic fibrosis drug Orkambi – to which Irish CF sufferers have pleaded for access.

The National Centre for Pharmacoeconomics (NCPE) carried out a cost-effectiveness assessment of the drug, which is manufactured by Vertex Pharmaceuticals.

The NCPE said 505 patients with Cystic Fibrosis would be potential candidates. It estimated that the five year budget impact to the HSE would be €391 million over five years.

Subscribe from just €1 for the first month!


What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

State paid GPs 40 per cent more during pandemic

Rosemary MacCabe: an essay

Tony O’Brien: Our kite-flying politicians haven’t yet given health workers a red cent

Have the scales finally tipped against dieting?